Roslind Anne, Knoop Ann S, Jensen Maj-Britt, Johansen Julia S, Nielsen Dorte L, Price Paul A, Balslev Eva
Department of Oncology, Herlev University Hospital, Copenhagen, Denmark.
Breast Cancer Res Treat. 2008 Nov;112(2):275-85. doi: 10.1007/s10549-007-9870-7. Epub 2007 Dec 22.
YKL-40 is a new biomarker in serum with a prognostic value in several localized and metastatic malignancies. The current knowledge regarding the biological functions of YKL-40 in cancer links YKL-40 to increased aggressiveness of the tumor. Utilizing tissue microarrays, YKL-40 protein expression in tumor tissue was assessed by immunohistochemistry in a cohort of 630 high-risk breast cancer patients with a median estimated potential follow-up time of 10 and 13 years for disease-free (DFS) and overall survival (OS), respectively. YKL-40 protein expression was found in malignant tumor cells and in inflammatory cells. High expression was associated with positive estrogen and progesterone receptor status and high tumor differentiation. Contrary to studies on serum YKL-40 as a prognostic biomarker, a high YKL-40 expression in tumor cells was not significantly associated with DSF and OS in univariate and multivariate analyses.
YKL-40是血清中的一种新生物标志物，在几种局部和转移性恶性肿瘤中具有预后价值。目前关于YKL-40在癌症中的生物学功能的认识将YKL-40与肿瘤侵袭性增加联系起来。利用组织芯片，通过免疫组织化学对630例高危乳腺癌患者的肿瘤组织中YKL-40蛋白表达进行了评估，这些患者无病生存期（DFS）和总生存期（OS）的估计中位潜在随访时间分别为10年和13年。在恶性肿瘤细胞和炎性细胞中发现了YKL-40蛋白表达。高表达与雌激素和孕激素受体阳性状态以及高肿瘤分化相关。与将血清YKL-40作为预后生物标志物的研究相反，在单因素和多因素分析中，肿瘤细胞中YKL-40的高表达与DFS和OS均无显著相关性。
